AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05273775
Drug: Omeprazole Enteric Capsules
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole Enteric Capsules single dose
Trial: NCT05273775
Drug: Vitamin K1 Tablets
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K1 Tablets once daily
Trial: NCT05273775
Drug: Digoxin Tablets
RxNorm normalized name: Digoxin Tablets
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin Tablets single dose
Trial: NCT05219799
Drug: Propranolol Hydrochloride
RxNorm normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regional forearm blockade of β-adrenergic receptors at 20 mcg/dL/min via brachial artery catheter during normoxia and hypoxia exposures
Trial: NCT05219799
Drug: Isoproterenol
RxNorm normalized name: Isoproterenol
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose response (1, 3, 6, and 12 ng/dL/min) regional infusion to assess β-adrenergic receptor responsiveness
Trial: NCT05219799
Drug: Phentolamine Mesylate
RxNorm normalized name: Phentolamine Mesylate
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This infusion will be for 10 min before baseline measurement (12 mcg/dL/min) and continue the infusion at a maintenance rate (5 mcg/dL/min).
Trial: NCT04223661
Drug: Lenalidomide Pill
RxNorm normalized name: lenalidomide Pill
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.
Trial: NCT04223661
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be administered at 20 mg per week. During weeks when the subject receives an infusion of daratumumab, dexamethasone will be administered on infusion days at a dose of 20 mg IV before the infusion.
Trial: NCT04223661
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab (1800 mg) will be administered by SC injection by manual push over approximately 3 - 5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. The volume of the SC solution will be 15 mL for the 1800 mg dose
Trial: NCT05222178
Drug: HMI-103
RxNorm normalized name: HMI-103
DrugBank: HMI-103 (DB17684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMI-103 is an AAVHSC15 capsid containing a functional copy of the human PAH gene
Trial: NCT05043298
Drug: IBI 360 Injection Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI 360 dose level of escalation IV Q3W Day 1 Sintilimab 200mg IV Q3W Day 1
Trial: NCT06731829
Drug: HRS-9231
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-9231
Trial: NCT06731829
Drug: Gadobutrol
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadobutrol
Trial: NCT06654297
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab will be given at at a dose of 200 mg intravenously on day 23 of a planned 28-day cycle, and two doses before surgery.
Trial: NCT06654297
Drug: Palbociclib(100mg)
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
Trial: NCT06654297
Drug: Palbociclib(125mg)
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib will be given at a dose of 125 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
Trial: NCT06072781
Drug: avutometinib
RxNorm normalized name: Avutometinib
DrugBank: Avutometinib (DB15254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avutometinib: administered orally
Trial: NCT06072781
Drug: Defactinib
RxNorm normalized name: Defactinib
DrugBank: Defactinib (DB12282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defactinib: administered orally
Trial: NCT06072781
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administered intravenously
Trial: NCT06072781
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT06072781
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT05741814
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gynecologist guided individualised propofol only sedation
Trial: NCT05878522
Drug: sisunatovir
RxNorm normalized name: Sisunatovir
DrugBank: Sisunatovir (DB15674)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 capsules administered Q12 hours for 5 doses
Trial: NCT05878522
Drug: moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 capsules of placebo administered Q12 hours for 4 doses, followed by a single tablet of moxifloxacin
Trial: NCT05878522
Drug: sisunatovir
RxNorm normalized name: Sisunatovir
DrugBank: Sisunatovir (DB15674)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 capsules administered Q12 hours for 5 doses
Trial: NCT06241677
Drug: alteplase or tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg) or tenecteplase (0.25mg/kg, maximum dosage 25mg) will be given
Trial: NCT06646198
Drug: Donafenib
RxNorm normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose donafenib, 100mg BID P.O. unless any evidence of disease progression or unacceptable side effects.
Trial: NCT06116786
Drug: JNJ-86974680
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-86974680 will be administered.
Trial: NCT06116786
Drug: Cetrelimab
RxNorm normalized name: Cetrelimab
DrugBank: Cetrelimab (DB15421)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrelimab will be administered.
Trial: NCT04973111
Drug: CT-868 as SC Injection
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-868
Trial: NCT04973111
Drug: Active Comparator as SC Injection
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT05185739
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pre-operative Pembrolizumab (200mg IV every 3 weeks) for 2 cycles
Trial: NCT05185739
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pre-operative Lenvatinib (8 or 12mg PO once daily according to bodyweight \<60gk≥) for 6 weeks
Trial: NCT05185739
Drug: Pembrolizumab and Lenvatinib
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pre-operative combination of pembrolizumab and lenvatinib at the standard doses and duration as per cohort 1 and 2
Trial: NCT00002099
Drug: Lentinan
RxNorm normalized name: lentinan
DrugBank: Lentinan (DB13480)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002099
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05888402
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of induction Toripalimab (240mg every 3 weeks) plus platinum-based doublet chemotherapy as induction chemoimmunotherapy.
Trial: NCT05325008
Drug: Immunosuppression reduction/modification + intravenous immunoglobulin
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intravenous immunoglobulin along with immunosuppression reduction/modification.
Trial: NCT05140616
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: After screening according to inclusion and exclusion criteria, patients meeting the criteria were enrolled. Treatment regimen: Chidamide 15mg biw po, lasted for 8 weeks. Pretransplant use of Chidamide for reasons other than cGVHD, such as for the treatment of leukemia or lymphoma, was permitted.All patients received systemic corticosteroid therapy for cGVHD prior to and during the study; concomitant use of other immunosuppressive therapies was also permitted, however, pre-existing corticosteroid and immunosuppressant doses must have been stable for 14 days before initiating Chidamide. Doses of concomitant corticosteroids and immunosuppressants could be tapered during the study as clinically indicated.
Trial: NCT06390124
Drug: Platelet Derived Growth Factor (PDGF)
RxNorm normalized name: Platelet-derived growth factor BB, recombinant
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reconstructive therapy of advanced peri-implantitis-related defects with anorganic bovine bone and allograft combined with PDGF
Trial: NCT04530565
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or IT
Trial: NCT04530565
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT04530565
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT04530565
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04530565
Drug: Ponatinib Hydrochloride
RxNorm normalized name: Ponatinib Hydrochloride
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04530565
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04530565
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05746481
Drug: Tiragolumab
RxNorm normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiragolumab (an investigational novel immune checkpoint inhibitor): 600 mg IV for induction treatment administered on Day 1 of each 21-day cycle for 4 cycles. Maintenance therapy will continue with tiragolumab on Day 1 of each 21-day cycle.
Trial: NCT05746481
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab (monoclonal antibody): 1200 mg IV administered on Day 1 of each 21-day cycle.
Trial: NCT05746481
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed (antifolate antineoplastic agent chemotherapy): 500 mg/m2 administered IV on Day 1 of each 21-day cycle.
Trial: NCT05746481
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 5 (alkylating agent chemotherapy): injection administered on Day 1 of each 21-day cycle.
Trial: NCT04176081
Drug: Darolutamide
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darolutamide will be administered orally as a tablet. Total daily dose is 1200 mg (2 tablets of 300 mg taken twice daily) for 6 months.
Trial: NCT04176081
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix is administered by subcutaneous injection. The first dose of degarelix is 240 mg followed by monthly doses of 80 mg for a total treatment duration of 6 months.
Trial: NCT05450822
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Healthy subjects and patients in Cohort III will undergo a 120 min. \[11C\]-UCB-J PET-MR brain scan followed by intravenous administration of levetiracetam after approx. 60 min. in a displacement paradigm. Before, during and after the intervention arterial spin labeling and resting-state functional MRI will be acquired.~To measure the radiolabelled tracer's arterial input function, including its radiolabelled metabolites, blood samples will be drawn during the PET scan from an arterial catheter.~The selected regions for the primary analyses are the epileptogenic lesion(s) (patients) and the neocortex, hippocampus, entorhinal cortex, fusiform gyrus, dorsolateral prefrontal cortex, ventrolateral prefrontal cortex, orbitofrontal cortex, striatum, anterior cingulate cortex and amygdala. \[11C\]-UCB-J binding, volume of distribution and SV2A occupancy will be quantified by analyzing the PET images with well-validated kinetic models.
Trial: NCT05450822
Drug: Levetiracetam Tablets
RxNorm normalized name: Levetiracetam Tablets
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients in Cohort II will be randomized to treatment with an ASM (levetiracetam) in accordance with standard treatment procedures. The patients will enter a 4 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to lamotrigine arm.
Trial: NCT06175403
Drug: Niacin
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of dose titrated from 10 µg·kg FFM-1·min-1 to 30 µg·kg for approximately 4.5 hours on one occasion
Trial: NCT05450822
Drug: Lamotrigine tablet
RxNorm normalized name: Lamotrigine Tablets
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in Cohort II will be randomized to treatment with an ASM (lamotrigine) in accordance with standard treatment procedures. The patients will enter a 6 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to levetiracetam arm.
Trial: NCT05977465
Drug: Empagliflozin 25 MG
RxNorm normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: treatment
Trial: NCT06720428
Drug: Artificial tear
RxNorm normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.3% Ali eye drops
Trial: NCT06719960
Drug: Dexmedetomidine group
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To evaluate cognitive function, Mini Mental State Examination (MMSE) was administered 3 times before the procedure and 2 hours and 24 hours after the procedure. Frailty level of the patient was determined using the frail frailty questionnaire. Each patient received 0.5µg/kg fentanyl (iv). In the dexmedetomidine group, in addition to propofol infusion at the same doses, dexmedetomidine 0.5 μg/kg-1 loading dose was administered within 10 minutes and then continued as infusion at a dose of 0.2-0.7 μg/kg/h.
Trial: NCT06719960
Drug: Propofol group
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To evaluate cognitive function, Mini Mental State Examination (MMSE) was administered 3 times before the procedure and 2 hours and 24 hours after the procedure. Frailty level of the patient was determined using the frail frailty questionnaire. Each patient received 0.5µg/kg fentanyl (iv). In the propofol group, propofol loading dose: 0.2-0.5mg/kg, maintenance infusion dose: 0.5-4mg/kg/h was continued.
Trial: NCT05262244
Drug: Bevacizumab-IRDye800CW
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab-800CW is administered to the patient and angiography is performed before and directly after tracer administration and after 48-96 hours.
Trial: NCT04466917
Drug: ABP 215
RxNorm normalized name: ABPC
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ABP 215 will be administered at a dose of 15 mg/kg IV
Trial: NCT04466917
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered at a dose of 15 mg/kg IV
Trial: NCT04466917
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered 175 mg/m2 IV
Trial: NCT04466917
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV
Trial: NCT05135793
Drug: Topoprazan
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 1 tablet contains 20 mg vonoprazan
Trial: NCT06388564
Drug: Axatilimab
RxNorm normalized name: Axatilimab
DrugBank: Axatilimab (DB16388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axatilimab will be administered at protocol defined dose.
Trial: NCT06388564
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib will be administered at protocol defined dose.
Trial: NCT05650580
Drug: TR115
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TR115 is supplied as tablet with dosage strength of 100mg. TR115 tablet will be administered orally on a continuous twice daily (BID) schedule and a treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations. TR115 tablets will be given until there appears evidence of progressive disease , intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Proposed daily dose (BID): 100mg, 200mg, 400mg, 800mg, 1200mg, 1600mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the Maximum Tolerated Dose (MTD) in order to better understand safety, Pharmacokinetic (PK) or Pharmacodynamic (PD).
Trial: NCT04736602
Drug: Triptorelin pamoate 15mg
RxNorm normalized name: Triptorelin Pamoate
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular injection (IM)
Trial: NCT06224036
Drug: Delamanid
RxNorm normalized name: delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Delamanid is a new drug developed by Otsuka Pharmaceutical Co., Ltd. in Japan to treat multidrug resistant tuberculosis. In 2014, Delamanid was conditionally approved for marketing by the European Medicines Agency and recommended for use in adult MDR-TB patients who cannot form an effective regimen due to drug resistance or tolerance reasons. In the same year, WHO recommended that Delamanid be conditionally used for long-term treatment of adult MDR-TB. In 2016, the WHO recommended widening the age range for Delamanid to 6-17 years old. In March 2018, Delamanid was listed in China.
Trial: NCT04994314
Drug: Control primer
RxNorm normalized name: SALICYLIC ACID 20 mg in 1 g TOPICAL LIQUID [Acne Oil Control Primer]
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional orthodontic primer
Trial: NCT05031780
Drug: Mitapivat
RxNorm normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitapivat tablets
Trial: NCT05788107
Drug: HLX51
RxNorm normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: anti-OX40 tetravalent agonistic humanized monoclonal antibody
Trial: NCT05080803
Drug: intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal administration
Trial: NCT05956522
Drug: Test Empagliflozin And Linagliptin Tablets
RxNorm normalized name: linagliptin and empagliflozin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: specification: 25 mg/5 mg, manufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd
Trial: NCT05956522
Drug: Reference Empagliflozin And Linagliptin tablets
RxNorm normalized name: linagliptin and empagliflozin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: specification: 25 mg/5 mg, manufacturer: Boehringer Ingelheim International GmbH \& Co. KG